Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib for Recurrent HCC After Liver Transplantation
NCT04237740Phase 3Unknown
- Sponsor
- Renji Hospital
- Start
- May 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Renji Hospital. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04237740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04237740.